Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (270)
- COVID-19 (163)
- Legislation (93)
- Safety monitoring and information (89)
- Compliance and enforcement (61)
- Manufacturing (51)
- Vaping hub (51)
- Labelling and packaging (34)
- Scheduling (national classification system) (26)
- Medicinal cannabis hub (25)
- Import and export (24)
- Sunscreens (16)
- Shortages and supply disruptions (14)
- Weight loss products (14)
- Committees and advisory bodies (9)
- Cosmetics (4)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1236 result(s) found, displaying 1 to 25
-
Regulatory decision noticesThis instrument is made under Schedule 5A to the Therapeutic Goods Regulations 1990 and Schedule 4 to the Therapeutic Goods (Medical Devices) Regulations 2002.
-
News articlesThe International Medical Device Regulators Forum (IMDRF) Software as a Medical Device (SaMD) Working Group has published the draft Essential Principles and Content of Predetermined Change Control Plans document for public consultation.
-
Media releasesThe TGA has updated its Advertising therapeutic goods on social media guidance to help advertisers to understand their responsibilities when promoting therapeutic goods via these platforms.
-
ACPharm Queensland issued infringement notices for alleged unlawful advertising of therapeutic goods
Media releasesWe have issued 5 infringement notices, totalling $99,000, to ACPharm Queensland Pty Ltd (ACPharm Queensland) for the alleged unlawful advertising of therapeutic goods. -
News articlesThe TGA is updating information for nitrosamine impurities and other nitroso-structure impurities in medicines including acceptable intakes (AI).
-
Regulatory decision noticesThe delegate believes, on reasonable grounds, that it is in the interests of public health or safety to give Hwangbo SS Pty Ltd and [REDACTED] directions under section 42YT of the Therapeutic Goods Act 1989.
-
News articlesWe have made changes to our website to make finding information easier. These improvements are based on your feedback.
-
Media releasesWe have issued a warning to online delivery service providers not to breach Australian laws regarding the supply and advertising of vaping goods.
-
Media releasesA coordinated crackdown on illegal vapes in southeast Queensland has led to a seizure of illegal vaping and tobacco products with a street value exceeding $8.8 million.
-
Media releasesProfessor Tony Lawler, Head of Australia’s Therapeutic Goods Administration, has been elected Chair of ICMRA, the International Coalition of Medicines Regulatory Authorities.
-
Regulatory decision noticesThe TGA has issued a direction notice to Hwangbo SS Pty Ltd and its executive officer in relation to vaping products under section 42DZK of the Therapeutic Goods Act 1989.
-
News articlesWe’re pleased to announce that improvements for industry users will roll out by the end of October.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesNew warnings on hepatotoxicity risk and monitoring recommendations have been added to the Product Information for Veoza (fezolinetant).
-
Regulatory decision noticesThe TGA has issued a direction notice to Iquality Group Pty Ltd and its executive officer in relation to the advertising of vaping goods under section 42DZK of the Therapeutic Goods Act 1989.
-
Regulatory decision noticesThe TGA has issued a direction notice to Iget Brands Pty Ltd and its executive officer in relation to the advertising of vaping goods under section 42DZK of the Therapeutic Goods Act 1989.
-
Regulatory decision noticesThis instrument is made under section 39 of the current Poisons Standard.
-
News articlesThere is growing interest in using software and artificial intelligence (AI) in healthcare settings, including where it is used to support people with mental health conditions.
-
News articlesThe GMP Guidelines on Chapter 1 - Pharmaceutical Quality System are being updated to reflect contemporary Quality Risk Management principles and further improve how Product Quality reviews are performed.
-
Regulatory decision noticesThis instrument is made under Schedule 5A to the Therapeutic Goods Regulations 1990 and Schedule 4 to the Therapeutic Goods (Medical Devices) Regulations 2002.
-
Safety updatesWe have received 2 serious adverse event cases in neonates in which EMLA (topical prilocaine/lidocaine cream) was applied for a circumcision procedure. Both cases were likely to have involved overdose.
-
News articlesThis Legislation Amendment makes changes to the way testing of goods is conducted under the Therapeutic Goods Regulations 1990.
-
News articlesWe've updated the Listed Medicine Compliance Reports database with the results of compliance reviews covering 18 listed medicines
-
Regulatory decision noticesListed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2025, which commenced on 19 September 2025.
-
Regulatory decision noticesThe TGA has identified a discrepancy between the wording of the ‘POTAS1’ warning statement available in the Code Tables compared to the requirements for potassium chloride and glucosamine sulfate potassium chloride in the Therapeutic Goods (Permissible Ingredients) Determination (the Determination).